Potassium Chloride Extended-Release Capsules are used for the treatment of patients with low potassium (hypokalemia). The capsules are packaged in bottles of 100-count (NDC 68462-357-01) and 500 ...

Mylan Launches Generic Xeloda Mylan announced its launch of Potassium Chloride Extended-Release Tablets, the generic version of Upsher-Smith's Klor-Con. Mylan announced its launch ...

Glenmark Pharmaceuticals Inc. issued a recall for some of its Potassium Chloride Extended-Release Capsules over a "failed dissolution" that may cause heart attacks.

Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), had U.S. sales of approximately $135.05 million for the 12 months ending June 30, 2014, ...

Watson plans to launch its Potassium Chloride Extended-Release product during the third quarter of 2008. The specific launch date will depend upon the timing of product validation activities and ...

Lupin announced that it has received final approval from the Food and Drug Administration (FDA) for its Potassium Chloride Extended Release Capsules, a generic version of Actavis' Potassium ...

Glenmark Laboratories recalled 114 batches of 750 mg Potassium Chloride Extended-Release Capsules in bottles of 100 (NDC No. 68462-357-01) and 500 (NDC No. 68462-357-05) capsules.

Potassium Chloride Extended Release tablets USP, 10 mEq (750 mg) and 20 mEq (1500 mg) were approved by the USFDA for treating patients with Hypokalemia.

Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due to Failed Dissolution. June 23, 2024.

K-Tab and potassium chloride extended-release tablets had a market value of approximately $346 million for the 12 months ended March 2020, according to IQVIA.

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has received approval from the U.S. Food and Drug Administration ...